Company Announcements

Expansion of company’s Panoramic offerings creates a unified gold standard for real-world evidence across the US, UK, and Germany to accelerate R&D pipeline decisions, setting a new standard to answer oncology’s most critical questions

NEW YORK--(BUSINESS WIRE)--Feb. 18, 2026-- Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced their first Panoramic datasets in the UK and Germany for patients with prostate cancer. Globally, prostate cancer affects nearly 1.5 million patients annually and has a rapidly evolving treatment landscape, yet real-world evidence remains limited and infeasible to study across international borders.

Flatiron is the first and only company to deliver global real-world data in this key oncology indication, leveraging proprietary AI and large language model capabilities to build on their Global Evidence Platform. The prostate cancer Panoramic datasets, which encompass the records of nearly 400,000 patients, unlock high-quality, source-level unstructured and structured EHR data across Germany, the UK, and the US. Built on a common data model across all regions, these datasets enable unprecedented interoperability—allowing researchers to seamlessly analyze patient outcomes and treatment patterns across markets to inform global evidence strategies.

"Flatiron is not just adding more data; we are building the singular destination for global oncology intelligence." said Kate Estep, Chief Product Officer at Flatiron Health. "By unifying fragmented global records into a single evidence platform, we are fundamentally changing how our customers develop therapies and—most importantly—when patients can access them."

This launch delivers immediate value to Flatiron's life science customers. The prostate Panoramic dataset builds on already available offerings to create a full scope of understanding for genitourinary cancers, specifically:

• The rich data provides all Prostate-Specific Membrane Antigen (PSMA) PET scan data, all prostate-specific antigen (PSA) values across the patient journey, and 19 Homologous Recombination Repair (HRR) genes, plus recurrence and progression details, enabling answers to key questions like how novel therapies are being used and which patients are benefiting most.
• Proprietary AI and large language model capabilities that unlock the full scale of the company’s network, with continuous recency to reflect the evolving treatment landscape and capture newly approved treatments as they enter the market.
• Unique patient-level EHR data captured through established site partnerships across Germany, the UK, and the US enable multiregional insights spanning early to late-stage disease and variations across markets.

All Flatiron datasets are validated against the company’s rigorous quality standards, reflect real-world clinical practice, and built by expert teams local to each geography, equipping researchers with the depth needed to answer oncology's most pressing questions. Combined with the company’s bladder Panoramic dataset—now spanning the full disease spectrum from early-stage through advanced and metastatic disease—these offerings are a clear answer to persistent evidence gaps across genitourinary cancers.

“The field of prostate cancer is evolving at a rapid pace, changing how care is sequenced from early-stage disease through metastatic CRPC and improving outcomes for patients. Yet critical evidence gaps remain, as we see significant regional variation in how novel therapies are used, and in how uneven access to advanced diagnostics differentially influences treatment decisions,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From a clinical perspective, Flatiron's global Panoramic datasets directly address these evidence gaps, enabling life science companies to increase confidence in decision-making earlier and accelerate development timelines across diseases and geographies, thereby bringing the next generation of precision medicine to all patients sooner.”

This launch marks the first in a series of global dataset expansions, with longitudinal breast cancer and non-small cell lung cancer (NSCLC) datasets planned for 2027. These expansions reinforce Flatiron Health as the gold standard in oncology data, intelligence, and technology. For over a decade, Flatiron has powered the highest-stakes decisions in cancer care and drug development with insights the industry did not have before—shaping what regulators, researchers, clinicians, and biopharma expect from oncology evidence and continuing to redefine that standard. By integrating rigorous real-world data with AI-driven intelligence, Flatiron is doing more than delivering datasets, it is transforming real-world patient experiences into decision-shaping insights that define the future of global cancer care.

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

About Panoramic Data
Panoramic data is Flatiron's foundational real-world data, flexibly designed to meet the needs of biopharma’s evolving research priorities with biomarker depth, scaled outcomes, and longitudinal data across 5M+ patients. Panoramic data is a comprehensive data solution that spans disease settings and supports assessments of high priority subgroups of interest. Flatiron offers Panoramic data across geographies, solid tumors, and hematologic malignancies to maximize use cases across oncology portfolios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218214663/en/

Nina Toor
press@flatiron.com

Source: Flatiron Health